TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
rubitecan Sensitive: D – Preclinical
|
rubitecan Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
teniposide Sensitive: D – Preclinical
|
teniposide Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
etoposide oral Sensitive: D – Preclinical
|
etoposide oral Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
pirarubicin Sensitive: D – Preclinical
|
pirarubicin Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
mitoxantrone Sensitive: D – Preclinical
|
mitoxantrone Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
idarubicin hydrochloride Sensitive: D – Preclinical
|
idarubicin hydrochloride Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
SA033 Sensitive: D – Preclinical
|
SA033 Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
daunorubicin Sensitive: D – Preclinical
|
daunorubicin Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
aclarubicin Sensitive: D – Preclinical
|
aclarubicin Sensitive: D – Preclinical
|
TOP2A overexpression
|
Multiple Myeloma
|
TOP2A overexpression
|
Multiple Myeloma
|
carfilzomib Resistant: D – Preclinical
|
carfilzomib Resistant: D – Preclinical
|